Mechanism of action
Triamcinolone binds to intracellular glucocorticoid receptors (GRs) forming a receptor-ligand complex that translocates to the nucleus. This complex binds to glucocorticoid response elements (GREs) on DNA, modulating gene transcription.
The anti-inflammatory effects result from multiple mechanisms:
- Inhibition of phospholipase A2 via lipocortin-1 (annexin-1) induction, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis
- Suppression of pro-inflammatory cytokines including IL-1, IL-2, IL-6, TNF-alpha, and interferon-gamma
- Inhibition of NF-κB transcription factor, a key regulator of inflammatory gene expression
- Decreased vascular permeability and reduced leukocyte migration to sites of inflammation
- Stabilization of lysosomal membranes preventing release of proteolytic enzymes
- Inhibition of fibroblast proliferation and collagen deposition
Triamcinolone has approximately five times the glucocorticoid potency of hydrocortisone but virtually no mineralocorticoid activity due to its 9-alpha-fluoro and 16-alpha-hydroxyl substitutions. The 16-hydroxyl group enhances topical potency and reduces systemic side effects when used dermally. It has an intermediate duration of action with a biological half-life of 18-36 hours.
- Triamcinolone has 5× the anti-inflammatory potency of hydrocortisone but negligible mineralocorticoid activity
- HPA axis suppression is the most significant systemic adverse effect; taper after >2-3 weeks of use to prevent adrenal crisis
- Topical triamcinolone 0.1% is mid-potency (Class IV-V); 0.5% is high-potency (Class II-III); use lower potencies on face and intertriginous areas
- Inhaled formulations require mouth rinsing after use to prevent oral candidiasis (thrush)
- Corticosteroids mask infection symptoms and increase opportunistic infection risk; screen for latent TB before prolonged therapy
- Contraindicated in systemic fungal infections and with live vaccines during immunosuppressive therapy
- CYP3A4 inhibitors (ketoconazole, ritonavir) increase triamcinolone levels and toxicity risk
- Combination with NSAIDs or aspirin increases GI ulceration and bleeding risk; monitor closely
Indications
Triamcinolone formulations are FDA-approved for numerous inflammatory and allergic conditions:
Dermatologic
- Inflammatory dermatoses (eczema, psoriasis, contact dermatitis, lichen planus)
- Keloids and hypertrophic scars (intralesional injection)
- Alopecia areata (intralesional)
Rheumatologic
- Inflammatory arthritis (intra-articular injection for knee, shoulder, hip)
- Tendinitis and bursitis (local injection)
- Systemic lupus erythematosus
- Rheumatoid arthritis
Respiratory
- Asthma (inhaled corticosteroid for maintenance)
- Allergic rhinitis (intranasal spray)
- Chronic obstructive pulmonary disease (in certain cases)
Ophthalmic
- Uveitis and other inflammatory eye conditions
- Macular edema (intravitreal injection)
- Allergic conjunctivitis
Oral
- Aphthous ulcers and oral inflammatory conditions (dental paste)
- Oral lichen planus
Other
- Systemic inflammatory conditions requiring oral corticosteroid therapy
- Adrenocortical insufficiency (less commonly used than hydrocortisone)
- Severe allergic reactions
The specific formulation and route depend on the condition being treated. Topical and inhaled forms are preferred when possible to minimize systemic exposure.
Pharmacokinetics
Absorption: Varies significantly by route. Oral triamcinolone is well absorbed from the gastrointestinal tract with peak plasma levels in 1-2 hours. Topical absorption depends on skin integrity, vehicle, and body site (highest on face, genitals, and occluded areas). Inhaled and intranasal formulations have primarily local effects with minimal systemic absorption. Intra-articular and intralesional injections provide sustained local drug release.
Distribution: Triamcinolone is approximately 68% protein-bound, primarily to albumin and transcortin (corticosteroid-binding globulin). It distributes into most body tissues and crosses the placenta. The volume of distribution is approximately 99 L.
Metabolism: Hepatic metabolism via cytochrome P450 enzymes (primarily CYP3A4) produces inactive metabolites including 6-beta-hydroxytriamcinolone. The acetonide ester formulations (most common) are hydrolyzed to the active free alcohol form.
Elimination: Metabolites are excreted primarily in urine with some biliary excretion. The plasma half-life is approximately 2-5 hours, but the biological half-life (duration of HPA axis suppression) is 18-36 hours due to tissue binding and receptor-mediated effects. Intra-articular injections may persist at the injection site for weeks to months.
Special populations: Hepatic impairment may reduce metabolism and increase systemic exposure. Renal impairment does not significantly affect elimination. Pediatric patients may have increased systemic absorption from topical formulations due to higher body surface area to weight ratio.
Adverse effects
Adverse effects depend on dose, duration, route, and formulation. Systemic effects are more common with oral, high-dose, or prolonged use.
Systemic effects
- Hypothalamic-pituitary-adrenal (HPA) axis suppression: Most significant with prolonged use; may lead to adrenal insufficiency upon abrupt discontinuation
- Cushing syndrome: Moon facies, central obesity, buffalo hump, striae, easy bruising (with chronic use)
- Hyperglycemia and diabetes mellitus: Glucocorticoids increase hepatic glucose production and insulin resistance
- Osteoporosis and fractures: Increased bone resorption and decreased formation
- Immunosuppression: Increased infection risk, including opportunistic infections and reactivation of latent tuberculosis
- Peptic ulcer disease: Especially when combined with NSAIDs
- Psychiatric effects: Mood changes, insomnia, psychosis, depression
- Myopathy: Proximal muscle weakness
- Avascular necrosis: Particularly of femoral and humeral heads
- Growth retardation: In children with prolonged use
- Cataracts and glaucoma: Posterior subcapsular cataracts and increased intraocular pressure
Topical/local effects
- Skin atrophy: Thinning, telangiectasia, striae (with prolonged topical use)
- Perioral dermatitis: Acneiform eruption around mouth
- Hypopigmentation: At injection sites or with topical use
- Local infection: Increased risk at injection sites
- Joint destruction: Rarely with repeated intra-articular injections (Charcot-like arthropathy)
Inhaled/intranasal effects
- Oral candidiasis: Thrush (use spacer and rinse mouth after use)
- Hoarseness and dysphonia: Due to local effects on vocal cords
- Nasal septum perforation: Rare with intranasal formulations
- Epistaxis: Nasal bleeding
Ophthalmic effects
- Increased intraocular pressure: Can precipitate glaucoma
- Cataract formation: With prolonged use
- Secondary ocular infections: Including fungal and viral
- Delayed wound healing: After ocular surgery
Contraindications and warnings
Absolute contraindications
- Hypersensitivity to triamcinolone or formulation components
- Systemic fungal infections (for systemic use)
- Live or live-attenuated vaccines (during immunosuppressive doses)
- Idiopathic thrombocytopenic purpura (for intramuscular administration)
Relative contraindications and warnings
- Active infections: May mask signs of infection and impair immune response; treat infection before starting corticosteroid when possible
- Tuberculosis: Screen for latent TB before prolonged therapy; reactivation risk
- Herpes simplex keratitis: Contraindicated in ophthalmic use due to risk of corneal perforation
- Peptic ulcer disease: Increased perforation and bleeding risk
- Diabetes mellitus: Monitor glucose closely; may require adjustment of antidiabetic medications
- Hypertension and heart failure: Fluid retention may exacerbate cardiovascular conditions
- Osteoporosis: Bone density monitoring recommended with prolonged use; consider calcium, vitamin D, and bisphosphonates
- Psychiatric disorders: May precipitate or exacerbate mood disorders and psychosis
- Myasthenia gravis: May worsen muscle weakness initially
- Glaucoma: Monitor intraocular pressure, especially with ophthalmic formulations
Pregnancy and lactation
Triamcinolone is FDA Pregnancy Category C (now replaced by PLAR system). Animal studies show teratogenic effects including cleft palate. Use in pregnancy only if benefits outweigh risks. First-trimester exposure carries highest risk. Infants born to mothers on chronic corticosteroids should be monitored for adrenal insufficiency.
Triamcinolone is excreted in breast milk in small amounts. Systemic effects in the infant are unlikely with topical, inhaled, or intranasal maternal use. High-dose systemic use may suppress infant growth and interfere with endogenous corticosteroid production.
Pediatric considerations
Children are at increased risk for systemic absorption from topical formulations and HPA axis suppression. Growth velocity should be monitored during chronic therapy. Use the lowest effective dose for the shortest duration. Inhaled corticosteroids may cause temporary growth deceleration but generally do not affect final adult height.
Geriatric considerations
Elderly patients are at higher risk for osteoporosis, glucose intolerance, hypertension, and infections. Use lower doses and monitor closely.
Drug interactions
CYP3A4 interactions
Inhibitors (increase triamcinolone levels): Ketoconazole, itraconazole, ritonavir, clarithromycin, grapefruit juice. May increase risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression.
Inducers (decrease triamcinolone levels): Rifampin, phenytoin, carbamazepine, phenobarbital. May reduce therapeutic efficacy; higher corticosteroid doses may be needed.
Pharmacodynamic interactions
- NSAIDs and aspirin: Increased risk of gastrointestinal ulceration and bleeding. Corticosteroids may also reduce salicylate levels.
- Warfarin: Variable effects on anticoagulation; monitor INR closely and adjust warfarin dose as needed.
- Antidiabetic agents: Corticosteroids increase blood glucose; may require increased doses of insulin or oral hypoglycemics.
- Diuretics: Hypokalemia risk increased, especially with loop and thiazide diuretics. Monitor potassium levels.
- Digoxin: Hypokalemia from corticosteroids increases digoxin toxicity risk.
- Live vaccines: Immunosuppressive doses may reduce vaccine efficacy and increase risk of vaccine-related infection. Avoid live vaccines during therapy.
- Fluoroquinolones: Increased risk of tendon rupture when combined with corticosteroids.
- Neuromuscular blocking agents: Prolonged neuromuscular blockade may occur, particularly with pancuronium.
- Anticholinesterases: Effects may be antagonized in myasthenia gravis patients.
- Estrogens: May increase corticosteroid binding protein levels and enhance corticosteroid effects.
Laboratory interactions
Corticosteroids may suppress skin test reactions and interfere with tests for bacterial infections. They may cause false-negative results in the nitroblue tetrazolium test for bacterial infection.
Clinical pearls
- Tapering is essential after prolonged use (>2-3 weeks of systemic therapy or high-dose topical use under occlusion) to prevent adrenal crisis from HPA axis suppression. Do not abruptly discontinue.
- Topical potency classification: Triamcinolone acetonide 0.1% is considered mid-potency (Class IV-V), while 0.5% is high-potency (Class II-III). Use lower potencies on face, genitals, and intertriginous areas.
- Injection technique matters: Intra-articular injections should be performed using aseptic technique. Avoid injecting into infected joints. Subcutaneous atrophy and hypopigmentation can occur with intralesional injections if injected too superficially.
- Inhaled steroid counsel: Patients using inhaled triamcinolone should rinse mouth after each use to reduce oral candidiasis risk and use a spacer device to improve lung deposition and reduce oropharyngeal deposition.
- Not for acute asthma: Inhaled corticosteroids including triamcinolone are for maintenance therapy only and have no role in acute asthma exacerbations. Use short-acting beta-agonists for acute symptoms.
- Watch for steroid-induced psychosis: Typically occurs within the first few weeks of high-dose therapy. Risk factors include higher doses, female sex, and history of psychiatric illness. Usually resolves with dose reduction or discontinuation.
- Pulse dosing for dermatologic conditions: For chronic inflammatory dermatoses, twice-weekly application of potent topical triamcinolone can maintain remission while minimizing side effects.
- Cosyntropin stimulation test: If HPA suppression is suspected after prolonged therapy, perform ACTH stimulation test before assuming normal function has returned. Recovery may take up to 12 months.
- Intravitreal injection pearls: Triamcinolone acetonide intravitreal injection for macular edema provides sustained intraocular drug levels for months but carries significant risk of cataract formation and glaucoma. Monitor IOP closely.
- Avoid intradermal injection near eyes: Periocular injections can cause blindness from retinal artery occlusion. Exercise extreme caution with injections in the glabellar region or nasolabial folds.
- Topical application enhancers: Occlusion (covering with plastic wrap) dramatically increases absorption and potency but also increases systemic absorption and local side effects. Reserve for thick, resistant plaques.
Practice questions
1. A 45-year-old woman with rheumatoid arthritis receives an intra-articular injection of triamcinolone acetonide for a persistently swollen right knee. Two weeks later, she develops fever, severe knee pain, and joint swelling. Synovial fluid aspiration shows 85,000 WBCs/μL with 92% neutrophils. Gram stain is negative. Which of the following mechanisms best explains why the infection was not apparent earlier?
2. A 28-year-old man with severe asthma has been using inhaled triamcinolone twice daily for 18 months. He presents to the emergency department with nausea, vomiting, and hypotension after abruptly stopping his medication 3 days ago due to financial constraints. His blood pressure is 85/50 mmHg. Laboratory studies show sodium 128 mEq/L, potassium 4.0 mEq/L, and glucose 65 mg/dL. Which of the following is the most likely diagnosis?
3. A 62-year-old woman with psoriasis has been applying triamcinolone acetonide 0.5% cream twice daily under occlusion for 8 weeks. She now presents with moon facies, central obesity, purple striae on her abdomen, and easy bruising. Fasting glucose is 185 mg/dL. Morning cortisol after 1 mg dexamethasone overnight is 1.2 μg/dL (normal >1.8). Which of the following best explains her presentation?
Frequently asked questions
How does triamcinolone work?
Triamcinolone binds intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene transcription. This suppresses inflammatory mediators by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, decreasing pro-inflammatory cytokine production (IL-1, IL-6, TNF-alpha), and inhibiting NF-κB transcription factor. It also reduces vascular permeability and leukocyte migration to inflammatory sites, providing broad anti-inflammatory and immunosuppressive effects with minimal mineralocorticoid activity.
What are the side effects of triamcinolone?
Side effects depend on route and duration of use. Systemic effects include HPA axis suppression (most important), Cushing syndrome with prolonged use (moon facies, central obesity), hyperglycemia, osteoporosis, increased infection risk, peptic ulcers, psychiatric symptoms, and cataracts. Topical use can cause skin atrophy, telangiectasia, hypopigmentation, and perioral dermatitis. Inhaled formulations may cause oral candidiasis and hoarseness. Intra-articular injections rarely cause joint destruction with repeated use. Abrupt discontinuation after prolonged therapy can precipitate adrenal crisis.
Is triamcinolone a strong steroid?
Triamcinolone is classified as an intermediate-potency corticosteroid with approximately five times the anti-inflammatory potency of hydrocortisone. In topical formulations, triamcinolone acetonide 0.1% is mid-potency (Class IV-V) while 0.5% is high-potency (Class II-III) in the seven-tier classification system. It is more potent than hydrocortisone but less potent than very high-potency agents like clobetasol. The 16-alpha-hydroxyl substitution enhances topical potency while minimizing systemic effects when used dermally.
Can you use triamcinolone on your face?
Triamcinolone can be used on the face but requires caution due to thinner facial skin and increased absorption. Lower-potency formulations (0.025% or 0.1%) should be used rather than high-potency versions, and treatment duration should be limited to avoid skin atrophy, telangiectasia, and perioral dermatitis. Never apply under occlusion on the face. For facial inflammatory conditions, use the lowest effective potency for the shortest duration possible, typically no more than 2-3 weeks continuously. Alternative lower-potency steroids like hydrocortisone may be safer for prolonged facial use.
Triamcinolone vs hydrocortisone — what is the difference?
Triamcinolone is approximately five times more potent than hydrocortisone as an anti-inflammatory agent but has virtually no mineralocorticoid activity, while hydrocortisone retains both glucocorticoid and mineralocorticoid effects. Triamcinolone has a longer duration of action (biological half-life 18-36 hours vs 8-12 hours) and is preferred for conditions requiring potent anti-inflammatory effects without sodium retention. Hydrocortisone is preferred for adrenal replacement therapy due to its mineralocorticoid activity and is safer for use on sensitive areas like the face. Triamcinolone carries higher risk of HPA axis suppression and systemic effects.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: A01AC01WHO ATC/DDD index: C05AA12
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.